/PRNewswire/ Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of.
/PRNewswire/ Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of.
/PRNewswire/ Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China,.
/PRNewswire/ Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China,.
Himalaya Therapeutics Announces Appointment of Howe Li as Chief Medical Officer
News provided by
Share this article
Share this article
SAN DIEGO, May 3, 2021 /PRNewswire/ Himalaya Therapeutics ( Himalaya ), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ( CAB ) technology platform, today announced the appointment of Howe Li, M.D., as chief medical officer. Dr. Li is a fantastic addition to our team. He has a depth of understanding of not only the patient, as a medical doctor, but also both global and China clinical trial design and execution said Brian Zhang, Ph.D., CEO of Himalaya. Dr. Li fills an absolutely critical role in our organization as we look to launch our clinical trials in Mainland China. He rounds out the executive management of Himalaya for now,